Identification of tumor vascular antigens by monoclonal antibodies prepared from rat-tumor-derived endothelial cells

✍ Scribed by Iwao Ohizumi; Shin-ichi Tsunoda; Kenji Taniguchi; Hiroyuki Saito; Keiko Esaki; Keiichi Koizumi; Hiroo Makimoto; Yukiko Wakai; Junji Matsui; Yasuo Tsutsumi; Shinsaku Nakagawa; Naoki Utoguchi; Yoshiyuki Ohsugi; Tadanori Mayumi

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: French
• Weight: 539 KB
• Volume: 77
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19980812)77:4<561::aid-ijc15>3.0.co;2-9

✦ Synopsis

We have reported the isolation and specific in vitro properties of tumor-derived endothelial cells (TEC) from rat KMT-17 fibrosarcomas transplanted into rats. To develop antibodybased tumor vascular targeting therapy for solid tumors, we have generated monoclonal antibodies (MAbs) using passive immunization of outside-out membrane vesicles of rat epididymal-fat-pad-derived capillary endothelial cells (FCEC) followed by active immunization of those of rat TEC. The MAbs produced were screened against TEC and FCEC. Of all cultured hybridomas, 75 (3.3%) of the secreted MAbs preferentially recognized TEC. We selected a total of 7 MAbs which detected antigens highly abundant in TEC, although 5 of the 7 MAbs were weakly positive for FCEC in cell-ELISA and FACS analyses. The antigens recognized by these MAbs, with the exception of MAb TES-7, were present on endothelial cells of tumor blood vessels in KMT-17 fibrosarcoma tissues, as shown by immunohistochemical analysis. Antigens of 40-and 80-kDa were recognized by MAbs TES-1, 7, 17, 21 and 26 and by MAbs TES-23 and 27 respectively. Although the function of these antigens, which are preferentially expressed on rat tumor-derived endothelial cells, is still unknown, we believe that future studies of such antigens will help elucidate the role of endothelial cells in tumor vasculature. Our results indicate that MAbs may provide a novel tool for the development of antibody-based therapy targeting tumor vasculature.